Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis
Απόστολος Τσάπας, Thomas Karagiannis, Panagiota Kakotrichi, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2116-2124
Closed Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1187
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 687
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S140-S157
Open Access | Times Cited: 677
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S158-S178
Open Access | Times Cited: 340
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S125-S143
Closed Access | Times Cited: 337
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, et al.
Diabetologia (2022) Vol. 65, Iss. 8, pp. 1251-1261
Open Access | Times Cited: 188
Metal-organic frameworks (MOFs) materials for pesticides, heavy metals, and drugs removal: Environmental safety
Brij Mohan, Anshul Kamboj, Virender Virender, et al.
Separation and Purification Technology (2023) Vol. 310, pp. 123175-123175
Closed Access | Times Cited: 108
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S181-S206
Closed Access | Times Cited: 73
Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control
Paul El Meouchy, Mohamad Wahoud, Sabine Allam, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12305-12305
Open Access | Times Cited: 71
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
Lori M. Laffel, Thomas Danne, Georgeanna J. Klingensmith, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 3, pp. 169-181
Open Access | Times Cited: 64
Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs
Silviu Stanciu, Emilia Rusu, Daniela Miricescu, et al.
Metabolites (2023) Vol. 13, Iss. 1, pp. 87-87
Open Access | Times Cited: 57
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1206-1222
Open Access | Times Cited: 30
Recent progress of MOF-based photocatalysts for environmental application and sustainability considerations
Ali Khatib Juma, Zulkifli Merican Aljunid Merican, Abdurrashid Haruna
Process Safety and Environmental Protection (2024) Vol. 208, pp. 391-435
Closed Access | Times Cited: 20
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 54
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 33, Iss. 6, pp. 424-442
Closed Access | Times Cited: 47
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Hong Ma, Yuhao Lin, Li-Zhen Dai, et al.
BMJ Open (2023) Vol. 13, Iss. 3, pp. e061807-e061807
Open Access | Times Cited: 41
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
Jonathan Goldney, Jack A. Sargeant, Melanie J. Davies
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1832-1845
Open Access | Times Cited: 38
Socioeconomic aspects of incretin-based therapy
Thomas Karagiannis, Eleni Bekiari, Απόστολος Τσάπας
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1859-1868
Open Access | Times Cited: 31
Advances in the management of type 2 diabetes in adults
Rodolfo J. Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000372-e000372
Open Access | Times Cited: 30
Pharmacological Support for the Treatment of Obesity—Present and Future
Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, et al.
Healthcare (2023) Vol. 11, Iss. 3, pp. 433-433
Open Access | Times Cited: 25
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
Alexia Bikou, Foteini Dermiki‐Gkana, Michail Penteris, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 5, pp. 611-619
Closed Access | Times Cited: 16
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
Jun Sung Moon, Shinae Kang, Jong Han Choi, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 4, pp. 546-708
Open Access | Times Cited: 12
Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence
Andrew S.P. Sharp, Khoa N. Cao, Murray Esler, et al.
European Heart Journal - Quality of Care and Clinical Outcomes (2024) Vol. 10, Iss. 8, pp. 698-708
Open Access | Times Cited: 11
Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis
Maarten Bak, Bea Campforts, Patrick Domen, et al.
Acta Psychiatrica Scandinavica (2024) Vol. 150, Iss. 6, pp. 516-529
Open Access | Times Cited: 11
Diabetic Kidney Disease
Anna Gaddy, Mohamed E. Elrggal, Hector Madariaga, et al.
Disease-a-Month (2025), pp. 101848-101848
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top